A 45-year-old woman from Mumbai with a history of TB treatment 2 years ago now presents with recurrent cough for 6 months. She had defaulted from treatment after 4 months. Sputum Gene Xpert MTB/RIF shows MTB detected with RIF resistance. Subsequent drug susceptibility testing reveals resistance to isoniazid, rifampicin, fluoroquinolone (levofloxacin), and amikacin. She is HIV-negative and has normal renal function. What is the most likely diagnosis, and which agent should be prioritized in her regimen?

Explanation

## Classification of Drug-Resistant TB ### Definition of XDR-TB **Key Point:** XDR-TB (Extensively Drug-Resistant TB) is defined as MDR-TB (resistance to INH + RIF) PLUS resistance to any fluoroquinolone AND at least one second-line injectable agent (amikacin, kanamycin, or capreomycin). ### DST Pattern in This Case | Drug | Resistance Status | |---|---| | Isoniazid (INH) | Resistant | | Rifampicin (RIF) | Resistant | | Levofloxacin (FQ) | Resistant | | Amikacin (Injectable) | Resistant | **Clinical Pearl:** This patient meets the definition of XDR-TB: MDR-TB + FQ resistance + injectable resistance. ## XDR-TB Classification Hierarchy ```mermaid flowchart TD A[Drug-Resistant TB]:::outcome --> B{INH + RIF resistant?}:::decision B -->|No| C[Drug-susceptible TB or mono/poly-resistant]:::outcome B -->|Yes| D[MDR-TB]:::outcome D --> E{FQ resistant?}:::decision E -->|No| F[MDR-TB only]:::outcome E -->|Yes| G{Injectable resistant?}:::decision G -->|No| H[Pre-XDR TB]:::outcome G -->|Yes| I[XDR-TB]:::urgent I --> J[Bedaquiline + Linezolid core agents]:::action ``` ## WHO-Recommended XDR-TB Regimen (2023) **High-Yield:** XDR-TB requires newer agents because conventional second-line drugs are ineffective. | Component | Agent | Duration | Rationale | |---|---|---|---| | **Core** | Bedaquiline | 6 months | Mycobacterial ATP synthase inhibitor; excellent XDR-TB efficacy | | **Core** | Linezolid | 5–7 months | Protein synthesis inhibitor; bacteriostatic but essential for XDR | | **Core** | Fluoroquinolone | 20 months | Moxifloxacin preferred (if susceptible); levofloxacin resistant here | | **Add if needed** | Clofazimine | 6 months | Slow-acting; added for additional coverage | | **Add if needed** | Cycloserine or Terizidone | 20 months | If poor response or additional support needed | **Mnemonic:** **BLiC** = **B**edaquiline, **Li**nezolid, (Fluoroquinolone), **C**lofazimine — the backbone of XDR-TB therapy. ## Why Bedaquiline and Linezolid Are Prioritized 1. **Bedaquiline:** - Novel mechanism (ATP synthase inhibition) - Highly active against MDR and XDR strains - Oral bioavailability - WHO-recommended core agent 2. **Linezolid:** - Excellent intracellular penetration - Bacteriostatic but critical for XDR-TB - Oral availability - Monitoring required: peripheral neuropathy, bone marrow suppression (especially at doses >600 mg/day) **Warning:** Linezolid at higher doses (600–1200 mg/day) carries risk of: - Peripheral neuropathy (dose- and duration-dependent) - Bone marrow suppression - Optic neuropathy (rare) - Regular monitoring of FBC and neurological status is mandatory ## Prognosis and Outcomes **Clinical Pearl:** XDR-TB has significantly worse outcomes than MDR-TB: - Treatment success rate: 40–50% (vs. 70–80% for MDR-TB) - Mortality: 15–25% - Requires longer treatment duration (20 months minimum) - Requires newer agents (bedaquiline, linezolid, clofazimine) ## Why This Patient Progressed to XDR-TB - **Default from treatment** after 4 months allowed: - Continued mycobacterial replication - Selection of resistant mutants - Accumulation of additional resistance mutations - Progression from drug-susceptible → MDR → XDR **Key Point:** Treatment default is a major driver of drug-resistance amplification and progression to XDR-TB. [cite:WHO TB Guidelines 2023, NTEP India TB Treatment Guidelines 2023]